Full-Time

Senior Manager

Tax Operations

Deadline 8/4/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$132.3k - $160.3k/yr

+ Incentive Cash + Stock Opportunities

Company Historically Provides H1B Sponsorship

Lawrence Township, NJ, USA

Hybrid

Hybrid work model with at least 50% onsite presence required.

Category
📘Accounting (1)
Required Skills
Power BI
SAP Products
Tableau
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor's degree in accounting, finance, or a related field; preferably with a Masters of Tax and/or CPA license.
  • 8+ years of US income tax provision, compliance, and tax accounting experience with a large multinational organization and preferably 2+ years of public accounting experience working in a complex manufacturing environment in the pharmaceutical industry.
  • In-depth knowledge of tax laws, regulations, and accounting principles, including GAAP and Non-GAAP accounting, legal entity forecasting and accounting.
  • Solid technology background with knowledge of OneSource Provision (knowledge of TaxStream is very beneficial), SharePoint, Excel along with other Microsoft Office products, SAP, and preferable experience with intelligent automation such as Alteryx, RPA, Power BI and Tableau.
  • Excellent communication and interpersonal skills to effectively collaborate with internal and external stakeholders, strong attention to detail and ability to work under tight deadlines.
Responsibilities
  • Support the preparation and review of GAAP and Non-GAAP effective tax rate (ETR) calculations, reconciliations, and supporting documentation.
  • Review and approval of assigned US entities’ income tax provisions under ASC 740-10 for projection cycles, quarterly actuals and annual reporting.
  • Responsible for the oversight of IRC Sec. 174 costs including the calculation, analysis, modelling and coordination across the tax teams for all US tax impacts.
  • Responsible for supporting the oversight, coordination and collaboration with internal stakeholders, outside consultants and our Tax Compliance Team for US tax credit incentives, specifically Research & Development and Orphan Drug credits.
  • Assist with US tax return compliance process, including liaising with external consultants, organizing and gathering source information, managing tax return studies and tax software administration. Provide support for the US return to provision (RTP) process and adjustments.
  • Lead and assist with tax technology strategic imperatives to ensure a cohesive and comprehensive approach to identification, recommendation and integration of tax technology implementations, automation, data wrangling, and analytics to continuously enhance processes and stakeholder value.
  • Support acquisition accounting and integration of acquired businesses, internal reorganizations, divestitures, and oversee accounting and tracking of collaboration agreements and joint ventures.
Desired Qualifications
  • Preferably with a Masters of Tax and/or CPA license.

Bristol Myers Squibb (BMS) develops and delivers medicines for serious diseases, focusing on oncology, immunology, and cardiovascular conditions. The company invests heavily in research and development to create new drugs, which are sold to hospitals and patients after receiving regulatory approval. BMS also produces generic drugs, making healthcare more affordable while ensuring quality and safety. Committed to sustainability, BMS aims to improve patient outcomes and support the development of biosimilars.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • Advancements in targeted protein degradation enhance therapeutic offerings in oncology.
  • Partnership with BioNTech could provide a competitive edge against Merck's Keytruda.

What critics are saying

  • Antitrust litigation over Pomalyst could impact BMS's market position in oncology.
  • Reliance on real-world data presents challenges in data quality and implementation.
  • High costs and technical challenges in space research could affect treatment feasibility.

What makes Bristol Myers Squibb unique

  • BMS collaborates with BioNTech for next-gen cancer immunotherapy, enhancing oncology portfolio.
  • Focus on real-world data strategies could lead to faster drug market entry.
  • Developing bone disease treatments in space positions BMS as a leader in innovative research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ISS National Lab
Jul 7th, 2025
This is Not the Time to Cut Space-enabled Medical Research

Bristol-Myers Squibb is developing novel bone disease treatments in space, and the National Stem Cell Foundation is studying 3D brain organoids derived from patients with Parkinson's disease in microgravity to observe disease progression more rapidly with the aim of identifying potential biomarkers for early diagnosis and therapeutic targets.

The Pharma Letter
Jun 26th, 2025
Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst

Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst.

Unlearn
Jun 24th, 2025
The Best 15 Minutes You'll Spend on Clinical Trials Today

At the 2025 "Digital Breakthrough for Pharma" Summit hosted by Bristol Myers Squibb, Unlearn's co-founder and machine learning scientist, Aaron Smith, took the stage to explain exactly how that vision is now a reality.

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.